CCNE1 Amplification as a Therapeutic Target.

Abstract

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. December 05, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.02267 Journal of Clinical Oncology - published online before print February 2, 2023 PMID: 36730890 CCNE1 Amplification as a Therapeutic Target George Au-Yeung , MBBS, PhD1,2xGeorge Au-YeungSearch for articles by this author; Linda Mileshkin , MBBS, MD1,2xLinda MileshkinSearch for articles by this author; and David D.L. Bowtell , PhD1,2xDavid D.L. BowtellSearch for articles by this author Show More 1Peter MacCallum Cancer Center, Melbourne, Victoria, Australia2Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia https://doi.org/10.1200/JCO.22.02267 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported by the National Health and Medical Research Council of Australia: APP1117044 (D.D.L.B.), APP1092856 (D.D.L.B.), and APP2008781 (D.D.L.B.).AUTHOR CONTRIBUTIONSConception and design: All authorsFinancial support: David D.L. BowtellCollection and assembly of data: George Au-Yeung, Linda MileshkinData analysis and interpretation: George Au-Yeung, Linda MileshkinManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTCCNE1 Amplification as a Therapeutic TargetThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).George Au-YeungResearch Funding: Roche/Genentech (Inst), AstraZeneca (Inst)David D.L. BowtellConsulting or Advisory Role: Exo TherapeuticsResearch Funding: Roche/Genentech, AstraZeneca, BeiGenePatents, Royalties, Other Intellectual Property: Henry Jackson Foundation INOVA HealthCare University of Melbourne (Inst)No other potential conflicts of interest were reported. Companion Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification